Luseogliflozin inhibits high glucose-induced TGF-2 expression in mouse cardiomyocytes by suppressing NHE-1 activity
Objective Sodium-glucose cotransporter-2 (SGLT2) inhibitors exhibit cardioprotective properties in patients with diabetes. However, SGLT2 is not expressed in the heart, and the underlying molecular mechanisms are not fully understood. We investigated whether the SGLT2 inhibitor luseogliflozin exerts...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-05-01
|
| Series: | Journal of International Medical Research |
| Online Access: | https://doi.org/10.1177/03000605221097490 |
| _version_ | 1828795870986895360 |
|---|---|
| author | Naoya Osaka Yusaku Mori Michishige Terasaki Munenori Hiromura Tomomi Saito Hironori Yashima Yoshie Shiraga Raichi Kawakami Makoto Ohara Tomoyasu Fukui Sho-ichi Yamagishi |
| author_facet | Naoya Osaka Yusaku Mori Michishige Terasaki Munenori Hiromura Tomomi Saito Hironori Yashima Yoshie Shiraga Raichi Kawakami Makoto Ohara Tomoyasu Fukui Sho-ichi Yamagishi |
| author_sort | Naoya Osaka |
| collection | DOAJ |
| description | Objective Sodium-glucose cotransporter-2 (SGLT2) inhibitors exhibit cardioprotective properties in patients with diabetes. However, SGLT2 is not expressed in the heart, and the underlying molecular mechanisms are not fully understood. We investigated whether the SGLT2 inhibitor luseogliflozin exerts beneficial effects on high glucose-exposed cardiomyocytes via the suppression of sodium-hydrogen exchanger-1 (NHE-1) activity. Methods Mouse cardiomyocytes were incubated under normal or high glucose conditions with vehicle, luseogliflozin, or the NHE-1 inhibitor cariporide. NHE-1 activity and gene expression were evaluated by the SNARF assay and real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis, respectively. Six-week-old male db/db mice were treated with vehicle or luseogliflozin for 6 weeks, and the hearts were collected for histological, RT-PCR, and western blot analyses. Results High glucose increased NHE-1 activity and transforming growth factor (Tgf )-β 2 mRNA levels in cardiomyocytes, both of which were inhibited by luseogliflozin or cariporide, whereas their combination showed no additive suppression of Tgf -β2 mRNA levels. Luseogliflozin attenuated cardiac hypertrophy and fibrosis in db/db mice in association with decreased mRNA and protein levels of TGF-β2. Conclusions Luseogliflozin may suppress cardiac hypertrophy in diabetes by reducing Tgf -β2 expression in cardiomyocytes via the suppression of NHE-1 activity. |
| first_indexed | 2024-12-12T04:12:52Z |
| format | Article |
| id | doaj.art-70384bedcd3a41af9453288197520c36 |
| institution | Directory Open Access Journal |
| issn | 1473-2300 |
| language | English |
| last_indexed | 2024-12-12T04:12:52Z |
| publishDate | 2022-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of International Medical Research |
| spelling | doaj.art-70384bedcd3a41af9453288197520c362022-12-22T00:38:35ZengSAGE PublishingJournal of International Medical Research1473-23002022-05-015010.1177/03000605221097490Luseogliflozin inhibits high glucose-induced TGF-2 expression in mouse cardiomyocytes by suppressing NHE-1 activityNaoya OsakaYusaku MoriMichishige TerasakiMunenori HiromuraTomomi SaitoHironori YashimaYoshie ShiragaRaichi KawakamiMakoto OharaTomoyasu FukuiSho-ichi YamagishiObjective Sodium-glucose cotransporter-2 (SGLT2) inhibitors exhibit cardioprotective properties in patients with diabetes. However, SGLT2 is not expressed in the heart, and the underlying molecular mechanisms are not fully understood. We investigated whether the SGLT2 inhibitor luseogliflozin exerts beneficial effects on high glucose-exposed cardiomyocytes via the suppression of sodium-hydrogen exchanger-1 (NHE-1) activity. Methods Mouse cardiomyocytes were incubated under normal or high glucose conditions with vehicle, luseogliflozin, or the NHE-1 inhibitor cariporide. NHE-1 activity and gene expression were evaluated by the SNARF assay and real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis, respectively. Six-week-old male db/db mice were treated with vehicle or luseogliflozin for 6 weeks, and the hearts were collected for histological, RT-PCR, and western blot analyses. Results High glucose increased NHE-1 activity and transforming growth factor (Tgf )-β 2 mRNA levels in cardiomyocytes, both of which were inhibited by luseogliflozin or cariporide, whereas their combination showed no additive suppression of Tgf -β2 mRNA levels. Luseogliflozin attenuated cardiac hypertrophy and fibrosis in db/db mice in association with decreased mRNA and protein levels of TGF-β2. Conclusions Luseogliflozin may suppress cardiac hypertrophy in diabetes by reducing Tgf -β2 expression in cardiomyocytes via the suppression of NHE-1 activity.https://doi.org/10.1177/03000605221097490 |
| spellingShingle | Naoya Osaka Yusaku Mori Michishige Terasaki Munenori Hiromura Tomomi Saito Hironori Yashima Yoshie Shiraga Raichi Kawakami Makoto Ohara Tomoyasu Fukui Sho-ichi Yamagishi Luseogliflozin inhibits high glucose-induced TGF-2 expression in mouse cardiomyocytes by suppressing NHE-1 activity Journal of International Medical Research |
| title | Luseogliflozin inhibits high glucose-induced TGF-2 expression in mouse cardiomyocytes by suppressing NHE-1 activity |
| title_full | Luseogliflozin inhibits high glucose-induced TGF-2 expression in mouse cardiomyocytes by suppressing NHE-1 activity |
| title_fullStr | Luseogliflozin inhibits high glucose-induced TGF-2 expression in mouse cardiomyocytes by suppressing NHE-1 activity |
| title_full_unstemmed | Luseogliflozin inhibits high glucose-induced TGF-2 expression in mouse cardiomyocytes by suppressing NHE-1 activity |
| title_short | Luseogliflozin inhibits high glucose-induced TGF-2 expression in mouse cardiomyocytes by suppressing NHE-1 activity |
| title_sort | luseogliflozin inhibits high glucose induced tgf 2 expression in mouse cardiomyocytes by suppressing nhe 1 activity |
| url | https://doi.org/10.1177/03000605221097490 |
| work_keys_str_mv | AT naoyaosaka luseogliflozininhibitshighglucoseinducedtgf2expressioninmousecardiomyocytesbysuppressingnhe1activity AT yusakumori luseogliflozininhibitshighglucoseinducedtgf2expressioninmousecardiomyocytesbysuppressingnhe1activity AT michishigeterasaki luseogliflozininhibitshighglucoseinducedtgf2expressioninmousecardiomyocytesbysuppressingnhe1activity AT munenorihiromura luseogliflozininhibitshighglucoseinducedtgf2expressioninmousecardiomyocytesbysuppressingnhe1activity AT tomomisaito luseogliflozininhibitshighglucoseinducedtgf2expressioninmousecardiomyocytesbysuppressingnhe1activity AT hironoriyashima luseogliflozininhibitshighglucoseinducedtgf2expressioninmousecardiomyocytesbysuppressingnhe1activity AT yoshieshiraga luseogliflozininhibitshighglucoseinducedtgf2expressioninmousecardiomyocytesbysuppressingnhe1activity AT raichikawakami luseogliflozininhibitshighglucoseinducedtgf2expressioninmousecardiomyocytesbysuppressingnhe1activity AT makotoohara luseogliflozininhibitshighglucoseinducedtgf2expressioninmousecardiomyocytesbysuppressingnhe1activity AT tomoyasufukui luseogliflozininhibitshighglucoseinducedtgf2expressioninmousecardiomyocytesbysuppressingnhe1activity AT shoichiyamagishi luseogliflozininhibitshighglucoseinducedtgf2expressioninmousecardiomyocytesbysuppressingnhe1activity |